Parkinson’s cell therapy bemdaneprocel shortens off time

Parkinson’s cell therapy bemdaneprocel shortens off time

Adults with Parkinson’s disease treated with the cell therapy bemdaneprocel spent less time in off periods, when symptoms were not adequately controlled despite medication use. That’s according to final published data from the exPDite Phase 1 trial (NCT04802733), which also showed that the cell therapy boosted the time…

1ST Biotherapeutics joins MJFF LRRK2 gene-targeting program

1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research…

What my ordeal with emergency back surgery taught me

In my last column, I mentioned that about a year after my diagnosis of early-onset Parkinson’s disease, I needed back surgery for a ruptured disc and a herniated disc in my lower spine. It was a harrowing experience, but I learned some important lessons. I’ve had lower back pain…

Blood test may detect Parkinson’s in earliest stages: Study

Scientists have developed a blood test to detect Parkinson’s disease in its very early stages, before a person experiences the first symptoms that would normally prompt a Parkinson’s diagnosis, a study showed. After identifying that people with Parkinson’s have alterations in two types of transfer RNA fragments (tRFs),…